LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma
Sponsor: Memorial Sloan Kettering Cancer Center
Listed as NCT03684980, this observational or N/A phase trial focuses on Central Nervous System Lymphoma and remains ongoing. Sponsored by Memorial Sloan Kettering Cancer Center, it has been updated 28 times since 2018, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
28 versions recorded-
Apr 16, 2026 — Present [daily]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting · Phase: EARLY_PHASE1 → None
-
Aug 2025 — Apr 2026 [monthly]
Recruiting EARLY_PHASE1
-
Jul 2025 — Aug 2025 [monthly]
Recruiting EARLY_PHASE1
-
Jun 2025 — Jul 2025 [monthly]
Recruiting EARLY_PHASE1
-
Feb 2025 — Jun 2025 [monthly]
Recruiting EARLY_PHASE1
▶ Show 23 earlier versions
-
Sep 2024 — Feb 2025 [monthly]
Recruiting EARLY_PHASE1
-
Aug 2024 — Sep 2024 [monthly]
Recruiting EARLY_PHASE1
-
Jul 2024 — Aug 2024 [monthly]
Recruiting EARLY_PHASE1
-
Jun 2024 — Jul 2024 [monthly]
Recruiting EARLY_PHASE1
-
May 2024 — Jun 2024 [monthly]
Recruiting EARLY_PHASE1
-
Apr 2024 — May 2024 [monthly]
Recruiting EARLY_PHASE1
-
Mar 2024 — Apr 2024 [monthly]
Recruiting EARLY_PHASE1
-
Aug 2023 — Mar 2024 [monthly]
Recruiting EARLY_PHASE1
-
Dec 2022 — Aug 2023 [monthly]
Recruiting EARLY_PHASE1
-
Sep 2022 — Dec 2022 [monthly]
Recruiting EARLY_PHASE1
-
Feb 2022 — Sep 2022 [monthly]
Recruiting EARLY_PHASE1
-
Sep 2021 — Feb 2022 [monthly]
Recruiting EARLY_PHASE1
-
Jan 2021 — Sep 2021 [monthly]
Recruiting EARLY_PHASE1
-
Jun 2020 — Jan 2021 [monthly]
Recruiting EARLY_PHASE1
-
May 2020 — Jun 2020 [monthly]
Recruiting EARLY_PHASE1
-
Mar 2020 — May 2020 [monthly]
Recruiting EARLY_PHASE1
-
Dec 2019 — Mar 2020 [monthly]
Recruiting EARLY_PHASE1
-
Nov 2019 — Dec 2019 [monthly]
Recruiting EARLY_PHASE1
-
Aug 2019 — Nov 2019 [monthly]
Recruiting EARLY_PHASE1
-
May 2019 — Aug 2019 [monthly]
Recruiting EARLY_PHASE1
-
Apr 2019 — May 2019 [monthly]
Recruiting EARLY_PHASE1
-
Dec 2018 — Apr 2019 [monthly]
Recruiting EARLY_PHASE1
Status: Not Yet Recruiting → Recruiting
-
Oct 2018 — Dec 2018 [monthly]
Not Yet Recruiting EARLY_PHASE1
First recorded
Eligibility Summary
The purpose of this study is to test the effects of a drug called Voraxaze when it's routinely given in combination with methotrexate and rituximab, the standard treatment for CNSL.
Contact Information
- Memorial Sloan Kettering Cancer Center
- University of Alabama at Birmingham
For direct contact, visit the study record on ClinicalTrials.gov .